Wednesday, November 25, 2009, 1:08am EST - Canadian Markets open in 8 hours and 22 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Elan Corp. plc (ELN)

 On Nov 24: 6.32 USD  Down 0.03 (0.47%)  
MORE ON ELN
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
ELAN CP PLC ADR (NYSE:ELN) Delayed quote dataEdit
After Hours: 6.32 0.00 (0.00%) as of 4:11pm EST on 11/24/09
Last Trade: 6.32 USD
Trade Time: Nov 24
Change: Down 0.03 (0.47%)
Prev Close: 6.35
Open: 6.35
Bid: N/A
Ask: N/A
1y Target Est: 20.57
Day's Range: 6.31 - 6.47
52wk Range: 4.61 - 9.13
Volume: 2,047,274
Avg Vol (3m): 4,424,210
Market Cap: 3.11B
P/E (ttm): N/A
EPS (ttm): -0.75
Div & Yield: N/A (N/A%)
Elan Corp. plc (ELN)
1d  5d  3m  6m  1y  2y  5y  max 
Free Annual Reports
 Add ELN to Portfolio   Download Data

HEADLINES
• 4 Platform Drugmakers to Invest In
at Motley Fool (Tue 3:20pm)
• UPDATE - HealthCor slams Biogen CEO for outsize pay package
at Reuters (Fri, Nov 20)
• Thursday Options Recap
at Seeking Alpha (Thu, Nov 12)
• When Rival Drug Makers Compare Notes On Safety Problems
at The Wall Street Journal Online (Wed, Nov 11)
• Cramer's Lightning Round - The Only Water Stock Worth Buying (11/10/09)
at Seeking Alpha (Wed, Nov 11)
• Lightning Round: Priceline.com, Citigroup, Transocean and More
at CNBC (Tue, Nov 10)
• Elan to Present at Lazard Capital Markets 6th Annual Healthcare Conference
Business Wire (Tue, Nov 10)
• Successful Pharmaceutical Company Mergers: Abbott Labs Is Leader
Wall Street Transcript (Mon, Nov 9)
• A Bear in the Bullpen: 3 Power Ratings Stocks Ready to Drop
TradingMarkets.com (Mon, Nov 9)
• Elan, Biogen change Tysabri label due to PML risk
at Reuters (Sat, Nov 7)
• Nice Quarter, Teva. What Will You Buy Next?
at Motley Fool (Tue, Nov 3)
• UPDATE - J&J slashing workforce, cites cost of drug research
at Reuters (Tue, Nov 3)
• Buffett to buy Burlington Northern in his biggest deal ever
Reuters (Tue, Nov 3)
More Headlines for ELN...
ANALYST
EPS Est (next year) (Dec-07) : N/A
EPS Est (in 2 years) (Dec-08) : N/A
Avg Rec (current)*: 3.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Elan Corporation, plc operates as a neuroscience-based biotechnology company primarily in Ireland and the United States. It operates through two segments, Biopharmaceuticals and Elan Drug Technologies.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices